Overview

PRGN-3006 Adoptive Cellular Therapy Relapsed or Refractory CD33-Positive AML or High Risk MDS

Status:
Not yet recruiting
Trial end date:
2035-04-01
Target enrollment:
Participant gender:
Summary
Thi study is to determine the safety and best dose of PRGN-3006 T Cells.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute